

# Clinical Commissioning Policy

# Sinus X-Ray

Category 1 Intervention - Not routinely commissioned -

Ref:	CMICB_Clin044
Version:	1
Purpose	This document is part of a suite of policies that the Integrated Care Board (ICB) uses to drive its commissioning of healthcare. Each policy in that suite is a separate public document in its own right but will be applied with reference to other policies in that suite.
Supersedes:	Previous Clinical Commissioning Group (CCG) Policy
Author (inc Job Title):	
Ratified by: (Name of responsible Committee)	ICB Board
Cross reference to other Policies/Guidance	
Date Ratified:	1 April 2023
Date Published and where (Intranet or Website):	1 April 2023 (Website)
Review date:	1 April 2026
Target audience:	All Cheshire & Merseyside ICB Staff and Provider organisations

#### Cheshire and Merseyside Integrated Care Board

This policy can only be considered valid when viewed via the ICB website or ICB staff intranet. If this document is printed into hard copy or saved to another location, you must check that the version number on your copy matches that of the one published.

Document control:		
Date:	Version Number:	Section and Description of Change
April 2023	1	Policy ratified by Cheshire & Merseyside ICB

#### 1. Introduction

- 1.1 This policy relates to the commissioning of interventions which optimise clinical effectiveness and represent value for money.
- 1.2 This document is part of a suite of policies which the Integrated Care Board (ICB) uses to drive its commissioning of healthcare. Each policy is a separate public document in its own right but should be considered alongside all the other policies in the suite as well as the core principles outlined in Appendix 1.
- 1.3 At the time of publication, the evidence presented per procedure/treatment was the most current available.

## 2. Purpose

2.1 This policy aims to ensure a common set of criteria for treatments and procedures across the region. This is intended to reduce variation of access to NHS services in different areas and allow fair and equitable treatment for all patients.

## 3. Policy statement

3.1 Use of x-ray or plain radiographs in the diagnosis of rhinosinusitis is not routinely commissioned.

#### 4. Exclusions

4.1 None

#### 5. Rationale

- 5.1 According to the Royal College of Surgeons and the British Society for Allergy and Clinical Immunology, there is no role for plain x-ray in the assessment of chronic rhinosinusitis.
- 5.2 X-ray imaging has limited usefulness because it underestimates any bony and soft tissue sinus pathology.

#### 6. Underpinning evidence

- 6.1 According to the Royal College of Surgeons' commissioning guide <sup>1</sup>, *rhinosinusitis* is defined as inflammation of the nose and paranasal sinuses. In acute sinusitis, there is complete resolution of symptoms within 12 weeks of onset; persistence of symptoms for more than 12 weeks is categorised as chronic rhinosinusitis. Acute rhinosinusitis usually has an infective aetiology. The aetiology of chronic rhinosinusitis is largely unknown but is likely to be multifactorial, with inflammation, infection and obstruction of sinus ventilation playing a part.
- 6.2 Chronic rhinosinusitis is a highly prevalent condition affecting 10% of the UK adult population. It is associated with significant reduction of quality of life, high health-care utilisation and significant absenteeism/presenteeism. Diagnosis is made by the presence of two or more persistent symptoms for at least 12 weeks, one of which should be either nasal obstruction and/or nasal discharge, and/or facial pain/pressure or anosmia.

- 6.3 The commissioning guide states there is no role for plain x-ray in assessment of chronic rhinosinusitis. Its limited usefulness is due to underestimation of bony and soft tissue sinus pathology. Imaging is usually reserved for those who fail medical therapy or have complicated infection/more serious conditions.
- 6.4 The British Society for Allergy and Clinical Immunology (BSACI) in its guidelines for the management of rhinosinusitis and nasal polyposis <sup>2</sup>, published in 2007, had previously confirmed that plain radiographs have no place in the routine management of rhinosinusitis. BSACI also stated that sinus x-rays are rarely helpful and CT scans should be reserved for patients failing medical therapy or those with atypical or severe disease. BSACI updated these guidelines in 2017 <sup>3</sup> and once again confirmed that radiology is not routinely recommended for simple rhinitis. However, when rhinosinusitis or nasal polyposis is suspected, especially non-responsive to medical therapy, CT scan is helpful.
- 6.5 More locally, a "not routinely commissioned" policy for the use of sinus x-ray in the diagnosis of rhinosinusitis is consistent with Mersey and North Staffordshire CCGs; Greater Manchester requires an individual exceptional funding request and in Shropshire, there is no policy.

#### **REFERENCES**

- 1 Commissioning guide: rhinosinusitis. Royal College of surgeons, London. 2013. <a href="https://www.rcseng.ac.uk/-/media/files/rcs/standards-and-research/commissioning/rhinosinusitis-commissioning-guide-for-republication.pdf">https://www.rcseng.ac.uk/-/media/files/rcs/standards-and-research/commissioning/rhinosinusitis-commissioning-guide-for-republication.pdf</a>
- 2 Scadding, GK., Durham, SR., Jones, SJ. BSACI guidelines for the management of rhinosinusitis and nasal polyposis. *Clinical and experimental allergy* 2007; **38**:260 275.
- **3** Scadding, GK., Kariyawasam, HH., Scadding, G. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised edition 2017; 1<sup>st</sup> edition 2007). *Clinical and experimental allergy* 2017; **47**:856 889.

#### 7. Force

7.1 This policy remains in force until it is superseded by a revised policy or by mandatory NICE guidance or other national directive relating to this intervention, or to alternative treatments for the same condition.

# 8. Coding

8.1 Office of Population Censuses and Surveys (OPCS)
 U21.7 Plain x-ray NEC and
 Z23 Nasal sinus

8.2 International classification of diseases (ICD-10)
None

# 9. Monitoring And Review

- 9.1 This policy may be subject to continued monitoring using a mix of the following approaches:
  - Prior approval process
  - Post activity monitoring through routine data
  - Post activity monitoring through case note audits
- 9.2 This policy will be kept under regular review, to ensure that it reflects developments in the evidence base regarding effectiveness and value.

# 10. Quality and Equality Analysis

10.1 Quality and Equality Impact Analyses have been undertaken for this policy at the time of its review.

### Appendix 1 - Core Objectives and Principles

# **Objectives**

The main objective for having healthcare commissioning policies is to ensure that:

- Patients receive appropriate health treatments
- Treatments with no or a very limited evidence base are not used; and
- Treatments with minimal health gain are restricted.

#### **Principles**

This policy aims to ensure a common set of criteria for treatments and procedures across the region. This is intended to reduce variation of access to NHS services in different areas and allow fair and equitable treatment for all patients.

Commissioning decisions by ICB Commissioners are made in accordance with the commissioning principles set out as follows:

- Commissioners require clear evidence of clinical effectiveness before NHS resources are invested in the treatment.
- Commissioners require clear evidence of cost effectiveness before NHS resources are invested in the treatment.
- Commissioners will consider the extent to which the individual or patient group will gain a benefit from the treatment.
- Commissioners will balance the needs of an individual patient against the benefit which could be gained by alternative investment possibilities to meet the needs of the community.
- Commissioners will consider all relevant national standards and consider all proper and authoritative quidance.
- Where a treatment is approved Commissioners will respect patient choice as to where a treatment is delivered, in accordance with the 'NHS Choice' framework.
- Commissioning decisions will give 'due regard' to promote equality and uphold human rights. Decision
  making will follow robust procedures to ensure that decisions are fair and are made within legislative
  frameworks.

#### Core Eligibility Criteria

There are a number of circumstances where a patient may meet a 'core eligibility criterion' which means they are eligible to be referred for the procedures and treatments listed, regardless of whether they meet the criteria; or the procedure or treatment is not routinely commissioned.

These core clinical eligibility criteria are as follows:

- Any patient who needs 'urgent' treatment will always be treated.
- All NICE Technology Appraisals Guidance (TAG), for patients that meet all the eligible criteria listed in a NICE TAG will receive treatment.
- In cancer care (including but not limited to skin, head and neck, breast and sarcoma) any lesion that has features suspicious of malignancy, must be referred to an appropriate specialist for urgent assessment under the 2-week rule.
- NOTE: Funding for all solid and haematological cancers are now the responsibility of NHS England.
- Reconstructive surgery post cancer or trauma including burns.
- Congenital deformities: Operations on congenital anomalies of the face and skull are usually routinely
  commissioned by the NHS. Some conditions are considered highly specialised and are commissioned in
  the UK through the National Specialised Commissioning Advisory Group (NSCAG). As the incidence of
  some cranio-facial congenital anomalies is small and the treatment complex, specialised teams, working
  in designated centres and subject to national audit, should carry out such procedures.
- Tissue degenerative conditions requiring reconstruction and/or restoring function e.g. leg ulcers, dehisced surgical wounds, necrotising fasciitis.
- For patients wishing to undergo Gender reassignment, this is the responsibility of NHS England and patients should be referred to a Gender Identity Clinic (GIC) as outlined in the Interim NHS England Gender Dysphoria Protocol and Guideline 2013/14.

### **Cosmetic Surgery**

Cosmetic surgery is often carried out to change a person's appearance to achieve what a person perceives to be a more desirable look.

Cosmetic surgery/treatments are regarded as procedures of low clinical priority and therefore not routinely commissioned by the ICB Commissioner.

A summary of Cosmetic Surgery is provided by NHS Choices. Weblink: <a href="http://www.nhs.uk/conditions/Cosmetic-surgery/Pages/Introduction.aspx">http://www.nhs.uk/conditions/Cosmetic-surgery/Pages/Introduction.aspx</a> and <a href="http://www.nhs.uk/Conditions/Cosmetic-surgery/Pages/Procedures.aspx">http://www.nhs.uk/Conditions/Cosmetic-surgery/Pages/Procedures.aspx</a>

#### **Diagnostic Procedures**

Diagnostic procedures to be performed with the sole purpose of determining whether or not a restricted procedure is feasible should not be carried out unless the eligibility criteria are met, or approval has been given by the ICB or GP (as set out in the approval process of the patients responsible ICB) or as agreed by the IFR Panel as a clinically exceptional case.

Where a General Practitioner/Optometrist/Dentist requests only an opinion the patient should not be placed on a waiting list or treated, but the opinion given and the patient returned to the care of the General Practitioner/Optometrist/Dentist, in order for them to make a decision on future treatment.

#### Clinical Trials

The ICB will not fund continuation of treatment commenced as part of a clinical trial. This is in line with the Medicines for Human Use (Clinical Trials) Regulations 2004 and the Declaration of Helsinki which stipulates that the responsibility for ensuring a clear exit strategy from a trial, and that those benefiting from treatment will have ongoing access to it, lies with those conducting the trial. This responsibility lies with the trial initiators indefinitely.

# Clinical Exceptionality

If any patients are excluded from this policy, for whatever reason, the clinician has the option to make an application for clinical exceptionality. However, the clinician must make a robust case to the Panel to confirm their patient is distinct from all the other patients who might be excluded from the designated policy.

The ICB will consider clinical exceptions to this policy in accordance with the Individual Funding Request (IFR) Governance Framework consisting of: IFR Decision Making Policy; and IFR Management Policy.